Pharmaceuticals · NYSE: TAK
Takeda earnings: results, call transcripts & KPI history
2 quarters · fiscal year ends March · next results expected around 28 Jan 2027
Latest: Q2 FY2026
Takeda's growth leaned on subcutaneous ENTYVIO and immunoglobulin demand, while new launches grew 17.3% at constant exchange rates but remain a small share of the business.
Demand centered on gastroenterology and plasma-derived therapies. ENTYVIO grew with the subcutaneous formulation in the U.S. and Europe, and subcutaneous immunoglobulins CUVITRU and HYQVIA grew at double-digit rates. Newer products added momentum: LIVTENCITY, VONVENDI, ADZYNMA, FRUZAQLA and QDENGA each grew on launch or expanded-use gains. TRINTELLIX benefited from U.S. pricing and payer mix. Takeda also discontinued its cell therapy research.
Quarters
KPI history
20-F filings
- 17 Jun 202620-F for the period ended 31 Mar 2026SEC ↗
- 25 Jun 202520-F for the period ended 31 Mar 2025SEC ↗
- 26 Jun 202420-F for the period ended 31 Mar 2024SEC ↗
- 28 Jun 202320-F for the period ended 31 Mar 2023SEC ↗
- 29 Jun 202220-F for the period ended 31 Mar 2022SEC ↗
- 29 Jun 202120-F for the period ended 31 Mar 2021SEC ↗
- 24 Jun 202020-F for the period ended 31 Mar 2020SEC ↗
- 27 Jun 201920-F for the period ended 31 Mar 2019SEC ↗